Technical Analysis for CIR - Circassia Pharmaceutical

Grade Last Price % Change Price Change
C 31.5901 -1.28% -0.41
CIR closed down 5.47 percent on Thursday, May 6, 2021, on 3.12 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical CIR trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish -1.28%
New Downtrend Bearish -1.28%
20 DMA Support Bullish -1.28%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.28%
Volume Surge Other -1.28%
Wide Bands Range Expansion -1.28%
Down 3 Days in a Row Weakness -1.28%
Down 4 Days in a Row Weakness -1.28%
Down 5 Days in a Row Weakness -1.28%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -6.68%
Older End-of-Day Signals for CIR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 2 hours ago
Fell Below 20 DMA about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Circassia Pharmaceutical Description

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Medicine Pharmaceuticals Disease Testing Targeting Diseases Medical Specialties Therapy Beta Oxide Smith Biopharmaceutical Respirator Immunology Therapies Immune System Respiratory Disease Allergy Chronic Obstructive Pulmonary Disease Respiratory Diseases Immunotherapy Respiratory Therapy Glaxosmithkline Organ Systems Asthma Long Acting Beta Adrenoceptor Agonist

Is CIR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.9
52 Week Low 19.86
Average Volume 963,179
200-Day Moving Average 27.12
50-Day Moving Average 29.12
20-Day Moving Average 31.91
10-Day Moving Average 34.23
Average True Range 2.17
ADX 27.36
+DI 18.69
-DI 20.38
Chandelier Exit (Long, 3 ATRs ) 31.40
Chandelier Exit (Short, 3 ATRs ) 34.00
Upper Bollinger Band 37.38
Lower Bollinger Band 26.44
Percent B (%b) 0.51
BandWidth 34.29
MACD Line 1.55
MACD Signal Line 1.60
MACD Histogram -0.0485
Fundamentals Value
Market Cap 127.2 Million
Num Shares 397 Million
EPS -33.70
Price-to-Earnings (P/E) Ratio -0.95
Price-to-Sales 1.93
Price-to-Book 1.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.28
Resistance 3 (R3) 36.47 35.23 35.56
Resistance 2 (R2) 35.23 34.14 35.14 35.32
Resistance 1 (R1) 33.62 33.47 33.00 33.43 35.09
Pivot Point 32.38 32.38 32.08 32.29 32.38
Support 1 (S1) 30.77 31.29 30.15 30.58 28.91
Support 2 (S2) 29.53 30.62 29.44 28.68
Support 3 (S3) 27.92 29.53 28.44
Support 4 (S4) 27.73